InterPATH-001 trial in progress: Adjuvant V940 (mRNA-4157) with pembrolizumab versus placebo in patients with high-risk stage II-IV melanoma
J.S. Weber,
J.J. Luke,
M.S. Carlino,
M.A. Khattak,
R. Meehan,
M. Brown,
J. Zhang,
C. Krepler,
J.P. Duic,
G.V. Long
Affiliations
J.S. Weber
NYU Langone Medical Center, New York, United States of America
J.J. Luke
UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, United States of America
M.S. Carlino
Sydney Medical School, Faculty of Medicine and Health Sciences, The University of Sydney, Camperdown and Melanoma Institute Australia, Sydney, and Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Sydney, Australia
M.A. Khattak
One Clinical Research and Edith Cowan University, Perth, Australia
R. Meehan
Moderna Inc., Cambridge, United States of America
M. Brown
Moderna Inc., Cambridge, United States of America
J. Zhang
Merck & Co., Inc., Rahway, United States of America
C. Krepler
Merck & Co., Inc., Rahway, United States of America
J.P. Duic
Merck & Co., Inc., Rahway, United States of America
G.V. Long
Melanoma Institute Australia, The University of Sydney, and Mater and Royal North Shore Hospitals, Sydney, Australia
